Immediate Management of Marked Hyperglycemia, Severe Hypertriglyceridemia, and Ketonuria in a Young Adult with Type 2 Diabetes

Urgent Assessment and Immediate Actions

This patient requires urgent evaluation for diabetic ketoacidosis (DKA) despite being asymptomatic. The combination of glucose >1000 mg/dL on urinalysis, ketonuria (15 mg/dL), and severe hypertriglyceridemia (525 mg/dL) raises concern for metabolic decompensation, even though serum glucose is 311 mg/dL and the patient reports no symptoms 1.

Critical First Steps

Obtain immediate point-of-care beta-hydroxybutyrate measurement to confirm or exclude ketoacidosis; a level >3.0 mmol/L indicates DKA regardless of serum glucose 1.
Check venous blood gas or basic metabolic panel to assess for anion gap acidosis (anion gap >12 suggests DKA) 1.
Temporarily discontinue Jardiance (empagliflozin) immediately due to risk of euglycemic DKA, particularly given the presence of ketonuria 1, 2.
Assess for precipitating factors: recent illness, reduced caloric intake, alcohol use, or prolonged fasting 1.

If DKA is confirmed (pH <7.3, bicarbonate <18 mmol/L, beta-hydroxybutyrate >3.0 mmol/L, anion gap >12), the patient requires hospitalization, IV insulin infusion, aggressive fluid resuscitation, and electrolyte replacement 1.

If DKA is excluded (normal pH, bicarbonate >18 mmol/L, beta-hydroxybutyrate <1.5 mmol/L), proceed with outpatient intensification as outlined below.

Glycemic Control: Immediate Intensification Required

This patient's glycemic control is severely inadequate. With fasting glucose 311 mg/dL, urinary glucose >1000 mg/dL, and pending HbA1c likely >10%, dual oral therapy (metformin + empagliflozin) has failed 1.

Insulin Initiation Protocol

Start basal insulin immediately alongside metformin continuation 1, 3:

Initial dose: 10 units of long-acting insulin (glargine or degludec) once daily at bedtime, or calculate 0.2 units/kg body weight given the severity of hyperglycemia 1, 3.
Titration: Increase by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL without hypoglycemia 1, 3.
Continue metformin at current dose (or optimize to 2000 mg daily if not already at maximum) because metformin reduces insulin requirements, provides cardiovascular benefit, and carries minimal hypoglycemia risk when combined with basal insulin 1, 3.

Empagliflozin Management Decision

Do not restart empagliflozin until:

Ketonuria resolves completely (repeat urinalysis showing negative ketones) 1, 2.
Glycemic control stabilizes with basal insulin (fasting glucose consistently 80–130 mg/dL for at least 2 weeks) 1.
Patient is educated about DKA warning signs and instructed to discontinue empagliflozin during illness, fasting, or reduced oral intake 1, 2.

Once safe to restart, empagliflozin 25 mg daily should be resumed because it provides critical cardiovascular and renal protection independent of glucose-lowering effect 1.

Three-Month Reassessment and GLP-1 RA Addition

If HbA1c remains >7% after 3 months of optimized metformin + basal insulin + empagliflozin, add a GLP-1 receptor agonist (semaglutide 0.25 mg weekly, titrated to 1.0 mg weekly) rather than intensifying insulin further 1, 3. GLP-1 RAs provide additional 0.6–0.8% HbA1c reduction, promote weight loss (2–5 kg), and carry minimal hypoglycemia risk 1, 3, 4.

Severe Hypertriglyceridemia: Urgent Lipid Management

Triglycerides of 525 mg/dL constitute severe hypertriglyceridemia (>500 mg/dL) and require immediate intervention to prevent acute pancreatitis 1, 5, 6.

Immediate Lipid-Lowering Strategy

Initiate high-intensity statin therapy immediately (atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily) because this patient has type 2 diabetes, which constitutes high cardiovascular risk requiring aggressive lipid management 3.
Target LDL-C <70 mg/dL (current LDL 86 mg/dL is above goal for a diabetic patient) 3.
Add fenofibrate 145 mg daily (or gemfibrozil 600 mg twice daily) specifically to address severe hypertriglyceridemia and reduce pancreatitis risk 3.
Counsel on strict dietary fat restriction (<15% of total calories from fat) until triglycerides fall below 500 mg/dL 3.
Avoid alcohol completely until triglycerides normalize, as alcohol markedly worsens hypertriglyceridemia 1, 5.

Expected Triglyceride Response

Triglycerides should improve substantially once glycemic control is achieved because hyperglycemia directly drives hepatic triglyceride synthesis 3. Recheck lipid panel at 3 months after insulin initiation; if triglycerides remain >200 mg/dL despite improved glucose control, continue fenofibrate long-term 3.

Cardiovascular Risk Reduction: HDL and Blood Pressure

HDL cholesterol of 27 mg/dL is severely low (<40 mg/dL in men is a major cardiovascular risk factor) 3. This will improve modestly with glycemic control, weight loss, and triglyceride reduction, but lifestyle modification (aerobic exercise ≥150 minutes/week, smoking cessation if applicable) is essential 1, 3.

Blood pressure management: Although not provided in the labs, ensure blood pressure is checked and controlled to <130/80 mmHg in this diabetic patient 1. If hypertensive, initiate an ACE inhibitor or ARB (particularly important given the microalbuminuria) 1.

Renal Protection: Addressing Microalbuminuria

Urine albumin-to-creatinine ratio of 14 mg/g is within normal range (<30 mg/g), indicating no current albuminuria 1. However, annual screening should continue 1. The normal eGFR of 129 mL/min/1.73 m² confirms preserved renal function, allowing full-dose metformin and empagliflozin (once restarted) 1.

Hepatic Considerations: Mild Transaminitis

ALT of 61 U/L (mildly elevated) and AST of 29 U/L (normal) suggest possible non-alcoholic fatty liver disease (NAFLD), common in poorly controlled diabetes with obesity 3. This will improve with glycemic control, weight loss, and triglyceride reduction 3. Recheck liver enzymes at 3 months; if ALT remains elevated, consider hepatology referral for further evaluation 3.

Monitoring Schedule and Follow-Up

Week 1–2 (Immediate)

Daily fasting glucose checks before breakfast to guide basal insulin titration 1, 3.
Repeat urinalysis to confirm ketone clearance before considering empagliflozin restart 1.
Recheck basic metabolic panel to ensure no acute kidney injury from volume depletion 2.

Month 1

Recheck fasting glucose, assess insulin dose adequacy, and confirm absence of hypoglycemia 1, 3.
Restart empagliflozin 25 mg daily if ketones cleared and glucose stable 1, 2.

Month 3

Measure HbA1c to assess treatment response (target <7%) 1, 3.
Recheck lipid panel to evaluate triglyceride response and statin efficacy 3.
Recheck liver enzymes (ALT, AST) to assess NAFLD improvement 3.
Add GLP-1 RA if HbA1c remains >7% despite optimized therapy 1, 3, 4.

Month 6 and Beyond

Continue HbA1c monitoring every 3 months until target achieved, then every 6 months 1, 3.
Annual lipid panel, renal function (eGFR, urine albumin-to-creatinine ratio), and comprehensive metabolic panel 1, 3.
Annual dilated eye exam and foot examination 1.

Critical Pitfalls to Avoid

Do not delay insulin initiation while waiting for oral agents to work; at this level of hyperglycemia, only combination therapy can achieve control 1, 3.
Do not restart empagliflozin until ketonuria resolves and glycemic control stabilizes, as SGLT2 inhibitors markedly increase DKA risk in the setting of metabolic stress 1, 2.
Do not discontinue metformin when adding insulin; metformin must remain foundational therapy unless contraindicated 1, 3.
Do not ignore severe hypertriglyceridemia; levels >500 mg/dL require urgent intervention to prevent pancreatitis 1, 5, 6.
Do not assume asymptomatic status excludes DKA; euglycemic DKA can present with minimal symptoms, and ketonuria in an SGLT2 inhibitor user mandates beta-hydroxybutyrate measurement 1, 2.
Do not wait beyond 3 months to intensify therapy if HbA1c remains above target; therapeutic inertia increases complication risk 1, 3.

Patient Education Priorities

DKA warning signs: Instruct patient to stop empagliflozin and seek urgent care if experiencing nausea, vomiting, abdominal pain, shortness of breath, or reduced oral intake 1, 2.
Hypoglycemia recognition: Teach symptoms (shakiness, sweating, confusion) and treatment (15–20 g fast-acting carbohydrate) 1, 3.
Insulin injection technique: Ensure proper subcutaneous administration, site rotation, and storage 1, 3.
Lifestyle modification: Emphasize 500-kcal daily deficit, ≥150 minutes/week moderate-intensity exercise, and strict fat restriction until triglycerides normalize 1, 3, 4.
Medication adherence: Stress importance of daily metformin, insulin, and statin therapy for long-term complication prevention 1, 3.

Help us tailor your experience